Yahoo · Oct 13, 2026
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
In the latest trading session, Novo Nordisk (NVO) closed at $38.06, marking a -1.35% move from the previous day.
NV
NASDAQ · NVO
Novo Nordisk A/S
Healthcare · Drug Manufacturers - General
$38.06
Up+$0.20 (+0.53%)
Updated Oct 14, 2026, 3:49 PM
SID Score
5.8/10
Composite research score
Smart Money
51/100
Neutral
- Market cap
- 223.45B
- P/E ratio
- 12.76
- Dividend yield
- 4.42%
- 52-week range
- $35.12 – $64.16
- Volume
- 9.26M
- Avg. volume
- 16.69M
Price performance · NVO
NVO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
NVO closed at $38.06 after 21 trading sessions, down 10.51% for the selected period.
- Last close
- $38.06
- Period change
- -10.51%
- Period low
- $37.32
- Period high
- $43.24
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $38.74 | $38.89 | $37.98 | $38.06 | 9.26M |
| Oct 12, 2026 | $38.85 | $38.85 | $38.26 | $38.58 | 8.72M |
| Oct 9, 2026 | $38.11 | $38.68 | $38.06 | $38.64 | 9.65M |
| Oct 8, 2026 | $37.80 | $38.23 | $37.505 | $38.18 | 11.82M |
| Oct 7, 2026 | $37.57 | $38.47 | $37.508 | $38.26 | 13.67M |
| Oct 6, 2026 | $37.35 | $37.53 | $36.845 | $37.53 | 13.7M |
| Oct 5, 2026 | $36.94 | $37.61 | $36.855 | $37.54 | 18.7M |
| Oct 2, 2026 | $37.635 | $37.65 | $37.17 | $37.32 | 10.26M |
| Oct 1, 2026 | $37.80 | $37.97 | $37.365 | $37.40 | 12.66M |
| Sep 30, 2026 | $38.05 | $38.77 | $37.885 | $37.91 | 21.56M |
| Sep 29, 2026 | $38.21 | $38.38 | $38.05 | $38.31 | 9.4M |
| Sep 28, 2026 | $38.40 | $38.8984 | $38.2323 | $38.71 | 11.43M |
| Sep 25, 2026 | $38.81 | $38.83 | $38.41 | $38.80 | 10.06M |
| Sep 24, 2026 | $37.95 | $38.7197 | $37.92 | $38.62 | 20.06M |
| Sep 23, 2026 | $38.90 | $39.14 | $38.16 | $38.17 | 18.44M |
| Sep 22, 2026 | $39.50 | $39.89 | $39.105 | $39.40 | 24.46M |
| Sep 21, 2026 | $41.05 | $41.17 | $39.54 | $39.80 | 49.34M |
| Sep 18, 2026 | $43.50 | $43.54 | $42.78 | $43.24 | 10.37M |
| Sep 17, 2026 | $41.98 | $43.44 | $41.96 | $43.19 | 12.95M |
| Sep 16, 2026 | $42.47 | $42.72 | $41.47 | $41.71 | 11.67M |
| Sep 15, 2026 | $42.725 | $43.00 | $42.40 | $42.53 | 8.86M |
Latest NVO news
The latest Smart Investors Daily articles mentioning NVO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NVO research
Overview
Company profile and research snapshot.
Company profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $47.50
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Sep 23, 2026 | JYSKE BANK | Hold | — |
| Sep 22, 2026 | BANCO SANTANDER | Outperform | — |
| Sep 22, 2026 | DNB CARNEGIE | Buy | — |
| Sep 22, 2026 | TD COWEN | Hold | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 12, 2026
4 Healthcare Stocks Worth Owning for the Next Decade
Two healthcare stocks that are leading their niches, and two that investors aren't giving enough credit to in the same niches.
Yahoo · Oct 12, 2026
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
Benzinga · Oct 12, 2026
BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40
BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and lowers the price target from $47 to $40.
AI research layers
Interpretive context generated from the platform’s current data sources.
Novo Nordisk A/S Stock Performance
Novo Nordisk A/S shares have experienced significant downward pressure across all measured timeframes, with the stock currently trading at $38.06 per SID market data. Over the past month, NVO has declined 10.42%, while the three-month and one-year losses stand at 21.38% and 34.25%, respectively. The stock is trading well below both its 50-day moving average of $43.26 and its 200-day moving average of $45.33, confirming a sustained bearish trend. The 14-day relative strength index registers at 41.6, approaching oversold territory but not yet triggering a traditional oversold signal below 30. Average daily trading volume stands at approximately 16.69 million shares, reflecting elevated investor activity during the selloff. Notably, NVO carries a beta of just 0.352 per SID market data, indicating the stock historically exhibits substantially lower volatility than the broader market, making the current magnitude of decline particularly noteworthy for this defensive healthcare name.
Novo Nordisk A/S Valuation Analysis
Novo Nordisk currently trades at a price-to-earnings ratio of 12.76, according to SID market data, a level that represents a notable compression from the premium multiples historically associated with the GLP-1 drug leader. The PEG ratio stands at 2.05, suggesting that even after the recent selloff, the stock's valuation relative to its expected earnings growth rate remains elevated. The company's price-to-book ratio of 8.43 reflects the asset-light, high-return-on-equity profile typical of major pharmaceutical companies, per SEC filings. Novo Nordisk's dividend yield has risen to 3.66% as the share price has declined, offering a meaningful income component for shareholders. With a market capitalization of approximately $223.45 billion, the company remains one of the largest healthcare firms globally. The current valuation metrics indicate that the market has repriced NVO meaningfully lower, compressing its earnings multiple toward levels more commonly seen in traditional pharmaceutical peers rather than high-growth biotech names.
Smart Money Activity for NVO
Novo Nordisk's composite smart money score stands at 51 out of 100, registering a neutral signal per SID market data. The institutional component scores a robust 23.0 out of 25, indicating that large asset managers and fund complexes maintain substantial positions in the stock according to 13F institutional filings. Insider activity scores 12.5 out of 25, reflecting a moderate level of insider transactions that does not strongly favor either accumulation or distribution based on SEC Form 4 filings. The dark pool activity score registers at just 5.0 out of 25, suggesting relatively limited off-exchange block trading activity in recent periods. Congressional trading interest scores 10.4 out of 25, pointing to some legislative member involvement but nothing particularly concentrated. The divergence between the high institutional score and the low dark pool score is notable, as it suggests that while large funds continue to hold NVO, there has been limited recent large-scale repositioning through non-public venues. Overall, the data reflects a holding pattern among sophisticated investors rather than decisive directional conviction.
Novo Nordisk A/S Earnings Outlook
Novo Nordisk's upcoming earnings calendar features four reporting dates in the forward-looking period, with analyst consensus estimates showing relative stability across quarters. The nearest scheduled report date is August 21, 2026, with an estimated earnings per share of $0.81, per analyst estimates. The subsequent reports on August 25 and August 28, 2026, carry identical consensus EPS estimates of $0.81, while the November 4, 2026, report carries a slightly lower estimate of $0.80 per share. The tight clustering of estimates around $0.80 to $0.81 suggests analysts currently project consistent quarterly profitability without meaningful sequential acceleration or deceleration. No actual results are yet available for these periods, and no earnings surprise data exists for comparison. At the current share price of $38.06, the stock trades at approximately 11.8 times the annualized forward estimate of roughly $3.23 based on these consensus figures, according to company earnings reports and analyst projections.
Wall Street Analyst Ratings for NVO
Recent Wall Street analyst activity on Novo Nordisk reflects a mixed but generally stable consensus, with no rating changes among the most recent coverage updates per SID consensus data. On September 23, 2026, Rothschild & Co Redburn reiterated a Buy rating, while Jyske Bank maintained its Hold recommendation. On September 22, 2026, three additional firms issued reaffirmations: Banco Santander reiterated an Outperform rating, DNB Carnegie maintained its Buy, and TD Cowen held its position at Hold, according to Wall Street analyst reports. Notably, none of the five most recent analyst actions involved a rating change, suggesting that despite the stock's 34.25% decline over the past year, analysts have not yet downgraded their fundamental views. The split between bullish ratings from Rothschild, Banco Santander, and DNB Carnegie against the neutral Hold stances from Jyske Bank and TD Cowen indicates a lack of uniform conviction on the near-term trajectory. The absence of any Sell ratings among recent coverage remains a distinguishing factor for the stock.
